JB Chemicals & Prescription drugs Ltd reported a 30 % decline in consolidated web revenue at Rs 101 crore for the fourth quarter of FY26, whereas the board beneficial a remaining dividend of ₹9.30 per fairness share (930 %) for the monetary 12 months, as the corporate navigates post-acquisition integration underneath the Gujarat-based Torrent Group.
Income from operations fell 5 % year-on-year to ₹904 crore throughout the quarter, impacted by one-off changes linked to integration actions, stock rationalisation and alignment of enterprise practices with the mother or father firm. Internet revenue after tax stood at Rs 101 crore, whereas adjusted web revenue after tax got here in at Rs 150 crore, excluding non-cash ESOP bills, distinctive gadgets and different one-offs, the corporate said.
The corporate mentioned India enterprise grew two % year-on-year to ₹526 crore in Q4, supported by regular home demand. For FY26, India operations rose 9 % to ₹2,461 crore, with the biosimilars (BGx) phase rising 11 %. In keeping with IQVIA MAT March 2026 information, India enterprise grew 11 %, forward of the trade’s 10 % progress, whereas the power portfolio expanded 19 % versus 14 % trade progress. Secondary market progress of 11 % mirrored underlying demand power throughout each the quarter and full 12 months interval.
Efficiency throughout the quarter was affected by one-offs, together with distribution community optimisation as a part of integration, discontinuation of low-margin commerce generics, alignment of commerce and gross sales insurance policies with the mother or father entity, and timing impacts from revised cut-off insurance policies throughout post-acquisition integration. Worldwide formulations income declined 9 % to ₹259 crore in Q4, whereas FY26 income rose two % to ₹1,154 crore. The phase was impacted by stock rationalisation, modifications in credit score practices following change of management, and cargo delays on account of container constraints, notably in the Center East.
The CDMO enterprise declined 22 % in the quarter on account of a excessive base in the earlier 12 months, whereas full-year income remained flat at ₹445 crore. The corporate mentioned the efficiency was influenced by elevated prior-year ranges and decrease buyer stock holdings. The corporate famous that Q4 represents a transitional part following change of management, with post-acquisition integration underway to align enterprise insurance policies and working frameworks with the mother or father organisation. It added that these impacts are short-term and expects efficiency to enhance progressively from April onwards, supported by synergy advantages and operational alignment.
Printed on Could 11, 2026
Source link
#Chemicals #posts #drop #PAT #declares #share #dividend
